Aarhus University upgrades its PExA instrument – continued trust in groundbreaking lung research
Aarhus University and Professor Torben Sigsgaard at the Department of Public Health have decided to upgrade their existing PExA 2.0 instrument to the latest version, PExA 2.1. The university is a long-standing user of PExA technology and has, since the initial installation in 2018, integrated it into their advanced research on how environmental factors affect respiratory health.
With its unique Climate Chambers, Aarhus University focuses on understanding how the environment impacts human airways and lung function. Since installing its first PExA instrument, the university has published several scientific articles based on data collected using the technology. The research includes studies of airway inflammation following exposure to particles from cooking, candle burning, and e-cigarettes. The results show changes in biomarkers such as SP-A and albumin, indicating mild inflammation in the small airways after exposure.
“That a leading institution like Aarhus University chooses to upgrade its existing system is a strong confirmation of the long-term value of our technology,” says Tomas Gustafsson, CEO of PExA AB. “It is especially gratifying to see customers who continue to invest in and advance their research using our instruments, which reinforces PExA’s strong position in the field of non-invasive airway sampling.”
Professor Torben Sigsgaard from Aarhus University comments:
“One of the major advantages of PExA is that the technology enables non-invasive sampling, which opens up the possibility for longitudinal studies and repeated sampling from the same individual without discomfort or health risks. This is essential for us to be able to monitor and understand the long-term effects of different types of exposures on the airways.”
The upgrade from PExA 2.0 to 2.1 includes, among other things, improved performance and increased precision in the collection and analysis of biomarkers from the small airways – enabling even more accurate research and results.
Click below to read scientific publications and learn more about Aarhus University’s Climate Chambers:
- Airway and systemic biomarkers of health effects after short-term exposure to indoor ultrafine particles from cooking and candles – A randomized controlled double-blind crossover study among mild asthmatic subjects
- An RCT of acute health effects in COPD-patients after passive vape exposure from e-cigarettes
- The Climate Chambers of The Department of Public Health at Aarhus University
For further information, please contact:
Tomas Gustafsson, CEO, info@pexa.se
About PExA AB:
PExA AB PExA AB (556956-9246) has developed the PExA 2.1, a patented research instrument that helps researchers intelligently collect biological samples from the smallest airways through a simple exhalation maneuver. PExA’s technology is currently used by prominent research groups in several different countries and research with the instrument has resulted in approximately 50 scientific publications, which serve as reference material for PExA’s method. The company’s long-term goal is to market and sell diagnostic instruments for popular diseases (e.g. lung cancer and COPD) to be used globally for diagnosis or general screening at facilities where care is offered. The company intends at the time it is relevant to sell to clinics to have developed more patient-friendly, flexible and commercial products, which means that PExA addresses a significantly wider market, which today includes several million patients globally.
PExA’s B share is listed on the Spotlight Stock Market.